Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management.
Anderson
Mark E
ME
Vanderbilt University Medical Center, Nashville, Tenn 37232-6300, USA. mark.anderson@mcmail.vanderbilt.edu
Al-Khatib
Sana M
SM
Roden
Dan M
DM
Califf
Robert M
RM
D000200:Action Potentials / Q000187:drug effects; D000595:Amino Acid Sequence; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D004353:Drug Evaluation, Preclinical; D000072237:ERG1 Potassium Channel; D004562:Electrocardiography / Q000187:drug effects; D051638:Ether-A-Go-Go Potassium Channels; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000235:genetics* / Q000503:physiopathology; D008396:Maryland; D008969:Molecular Sequence Data; D010641:Phenotype; D015221:Potassium Channels / Q000187:drug effects / Q000235:genetics*; D024642:Potassium Channels, Voltage-Gated; D017410:Practice Guidelines as Topic; D016171:Torsades de Pointes / Q000139:chemically induced*; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
D000889:Anti-Arrhythmia Agents; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; C092509:KCNH6 protein, human; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG